Cost-utility evaluation of influenza vaccination in patients with existing coronary heart diseases in Thailand

1. Aekplakorn W. Thai Health 2007 [Internet]. Bangkok: Institute for Population and Social Research Mahidol University; 2007; [cited 2012 June 5]: Available from: http://www.hiso.or.th/hiso/picture/reportHealth/ThaiHealth2007/ENG2007-Health-Indicators5.pdfSearch in Google Scholar

2. Gurfinkel E, Mautner B. Secondary prevention of coronary artery disease. Flu vaccinations and new evidence of the role of infection in acute coronary syndromes. Rev Esp Cardiol. 2002; 55:1009-12.10.1016/S0300-8932(02)76747-XOpen DOISearch in Google Scholar

3. Davis MM, Taubert K, Benin AL, Brown DW, Mensah GA, Baddour LM, et al. Influenza vaccination as secondary prevention for cardiovascular disease; a science advisory from the American Heart Association/ American College of Cardiology. J Am Coll Cardiol. 2006; 48:1498-502.10.1016/j.jacc.2006.09.00417010820Open DOISearch in Google Scholar

4. CDC Home [Internet]. Centers for Disease Control and Prevention; 2011; [updated 2012 April 16; cited 2012,June 5]: Available from: http://www.cdc.gov/flu/professionals/acip/Search in Google Scholar

5. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease. Circulation. 2006; 113:2363-72.10.1161/CIRCULATIONAHA.106.17451616702489Search in Google Scholar

6. Nease RF, Kneeland T, O∩onnor GT, Sumner W, Lumpkins C, Shaw L. et al. Variation in patient utilities for outcomes of the management of chronic stable angina implications for clinical practice guidelines. JAMA. 1995; 273:1185-90.10.1001/jama.1995.03520390045031Search in Google Scholar

7. National Health Security Office. The annual report of universal health insurance coverage 2009. [Internet]. Bangkok: National Health Security Office, Thailand [cited 2012 June 26]. Available from: http://www.nhso.go.th/FrontEnd/page-about_result.aspxSearch in Google Scholar

8. Hoerger TJ, Hicks KA, Bethke AD. Health, social, and economics research; technical report: a Markov model of disease progression and cost-effectiveness for type 2 diabetes. NC; 2004.Search in Google Scholar

9. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. AJPH. 1987; 77:1417-26.10.2105/AJPH.77.11.1417Search in Google Scholar

10. Board of directors to reduce the risk factors that affect chronic disease. Thailand healthy lifestyle strategic plan 2011-2010: situation of health problem and chronic non-communicable disease result from lifestyle change. Bangkok: Office of the National Economic and Social Development Board/Ministry of Public Health.Search in Google Scholar

11. Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Goldman PA, Williams LW, et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA. 1997; 277:535-42.10.1001/jama.1997.03540310033031Search in Google Scholar

12. Keller T, Weeda VB, van Dongen CJ, Levi M. Influenza vaccines for preventing coronary heart disease. Cochrane Database Syst Rev. 2008; 3:CD005050. doi: 10.1002/14651858.CD005050.pub2.Search in Google Scholar

13. Praditsuwan R, Assantachai P, Wasi C, Phuthavatana P, Kositanont U. The efficacy and effectiveness of influeza vaccination among Thai elderly persons living in the community. J Med Assoc Thai. 2005; 88: 256-64.Search in Google Scholar

14. Nease RF, Kneeland T, O’Connor GT, Sumner W, Lumpkins C, Shaw L, et al. Variation in patient utilities for outcomes of the management of chronic stable angina. JAMA. 1995; 273:1185-90.10.1001/jama.1995.03520390045031Search in Google Scholar

15. Hayashino Y, Nagata-Kobayashi S, Morimoto T, Maeda K, Shimbo T, Tsuguya F. Cost-effectiveness of screening CAD in diabetics cost-effectiveness of screening for coronary artery disease in asymptomatic patients with type 2 diabetes and additional atherogenic risk factors. J Gen Intern Med. 2004; 19: 1181-91.10.1111/j.1525-1497.2004.40012.x149259415610328Open DOISearch in Google Scholar

16. Tsevat J, Goldman L, Soukup RJ, Lamas GA, Connors KF, Chapin CC, et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making. 1993; 13:161-5.10.1177/0272989X93013002108483401Open DOISearch in Google Scholar

17. Pradas VR, Villar FA, Martinex-Zarate M. Use of European quality of life-5 dimensions (EQ-5D) questionnaire to value the health related quality of life variation because of influenza. Publicado en Gac Sanit. 2009; 23:104-8.Search in Google Scholar

18. Anukulsawat P, Sritara P, Teerawattananont Y. Treatment cost of acute myocardial infarction at Ramathibodi Hospital. Thai Heart J. 2006; 16:132-43.Search in Google Scholar

19. Simmermana JM, Lertiendumrong J, Dowell SF, Uyeki T, Olsen SJ, Chittaganpitch M, et al. The cost of influenza in Thailand. Vaccine. 2006; 24:4417-26.10.1016/j.vaccine.2005.12.06016621187Search in Google Scholar

20. Riewpaiboon A. Standard cost lists for health technology assessment. Bangkok: Health Intervention and Technology Assessment Program; 2009.Search in Google Scholar

21. Aungkulanon S, Lertiendumrong. International Health Policy Program, Thailand Presentation [Internet]. Bangkok: International Health Policy Program, Thailand; 2009 Dec 3 [cited 2012 June 26]. Available from: https://ihppthaigov.net/presentation/attachjournal/267/PPT/PPT1.pptSearch in Google Scholar

22. Department of Provincial Administration. Ministry of Interior. [Internet]. Bangkok: Department of Provincial Administration. Ministry of Interior: 2011 Dec 31; [cited 2012 June 25]. Available from http://www.dopa.go.th/Search in Google Scholar

23. Thailand. Thai Burden of Disease Working Group: 2009/ International Health Policy Program Thailand. Burden of Disease Thailand, 2009. Bangkok: Ministry of Public Health; 2011. Search in Google Scholar